This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:protocol:olmesartan:kidney_disease [10.25.2018] – [Benefits of angiotensin receptor blockers] sallieq | home:protocol:olmesartan:kidney_disease [08.13.2019] – [Benefits of olmesartan for patients with kidney disease] sallieq | ||
---|---|---|---|
Line 7: | Line 7: | ||
- | ===== Subclinical kidney infection ===== | ||
- | Subclinical - that is to say, undetected or undetectable - kidney disease is common in patients with [[home: | ||
- | |||
- | Once patients activate the [[home: | ||
Line 45: | Line 41: | ||
// | // | ||
- | ===== Benefits | + | |
+ | " | ||
+ | |||
+ | ===== Subclinical kidney infection ===== | ||
+ | |||
+ | Subclinical - that is to say, undetected or undetectable - kidney disease is common in patients with [[home: | ||
+ | |||
+ | Once patients activate the [[home: | ||
+ | ===== Olmesartan benefits | ||
According to a 2008 commentary appearing in //Nature//: | According to a 2008 commentary appearing in //Nature//: | ||
Line 55: | Line 59: | ||
MP patients with kidney inflammation and their healthcare practitioners should be extremely comforted by the fact that the patient is taking olmesartan. This is due to the great number of studies, which have found that olmesartan and other ARBs protect the kidneys from the effects of inflammation and cytokine damage. | MP patients with kidney inflammation and their healthcare practitioners should be extremely comforted by the fact that the patient is taking olmesartan. This is due to the great number of studies, which have found that olmesartan and other ARBs protect the kidneys from the effects of inflammation and cytokine damage. | ||
- | The benefits of olmesartan on patients with kidney inflammation include: | + | The benefits of olmesartan on patients with kidney inflammation include |
* decreased insulin resistance, fewer symptoms of the metabolic syndrome, and decreased inflammation in patients with chronic kidney disease.(({{pubmed> | * decreased insulin resistance, fewer symptoms of the metabolic syndrome, and decreased inflammation in patients with chronic kidney disease.(({{pubmed> | ||
Line 87: | Line 91: | ||
==== Animal studies ==== | ==== Animal studies ==== | ||
+ | |||
+ | [[http:// | ||
Ability to affect the local renin-angiontensin sytem (RAS) and thus improve renal injury and function in a rat model of potentially progressive glomerulosclerosis.(({{pubmed> | Ability to affect the local renin-angiontensin sytem (RAS) and thus improve renal injury and function in a rat model of potentially progressive glomerulosclerosis.(({{pubmed> | ||
Line 95: | Line 101: | ||
{{tag> | {{tag> | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
+ | |||
+ | Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate < | ||